Compare HubSpot Inc (HUBS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Eli Lilly And Co — how do they compare? HubSpot Inc trades at $215.64 (market cap $11.84B), while Eli Lilly And Co trades at $1,175.96 (market cap $1.02T). The key difference: Eli Lilly And Co is far larger — about 86.1× HubSpot Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| HUBS | LLY | |
|---|---|---|
Market Cap | $11.84B | $1.02T |
Sector | Technology | Health |
52-Week High | $560.90 | $1.24K |
52-Week Low | $170.39 | $625.65 |
Enterprise Value | $10.39B | $1.06T |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $218.58, down 2.53% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, reaching $3.13B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with an 80.85% buy rating and a $261.67 consensus price target, suggesting significant upside potential from current levels.
The outlook for HUBS is favorable due to robust customer growth and AI-driven product expansion, though high valuation multiples (P/E of 121.69) pose a risk if growth slows. Key risks include competitive pressures in the CRM space and market volatility. The stock presents a growth opportunity supported by solid fundamentals and positive analyst coverage, but investors should be cautious of premium pricing relative to earnings.
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
